Eugene Chung, MD
Advanced Heart Failure and Transplant Cardiology · Cincinnati, OHNPI 1003893926
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $183,549 of the $296,909 with a category attached, or 61.8%. 31 manufacturers reported payments, led by Abbott at 32.6% of the total. Reporting peaked in 2019 at $105,599 and has fallen 85.8% since, to $14,963 in 2025. Among advanced heart failure and transplant cardiology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 486 payments — averaging $610.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$97K
- Boehringer Ingelheim$65K
- Cvrx, Inc.$54K
- Livanova USA, Inc.$43K
- Lilly USA, LLC$17K
- Medtronic$10K
- plus $11K from 25 others
Across 131 payments — averaging $4034.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$225K
- Edwards Lifesciences$156K
- Abbott$72K
- Amgen$48K
- Inspire Medical Systems, Inc.$21K
- Boston Scientific$7K
What the payments were for
- Consulting fees$183,54962%
- Speaking & faculty fees$88,28030%
- Travel & lodging$8,2013%
- Food & beverage$16,6596%
- Education$2190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 165 | $96,885 |
| Boehringer Ingelheim | 59 | $65,124 |
| Cvrx, Inc. | 34 | $54,394 |
| Livanova USA, Inc. | 51 | $42,701 |
| Lilly USA, LLC | 12 | $16,775 |
| Medtronic(2 entities) | 42 | $9,697 |
| Boston Scientific | 3 | $4,301 |
| AstraZeneca | 12 | $1,931 |
| Bayer | 11 | $1,372 |
| Atricure, Inc. | 2 | $329 |
| Edwards Lifesciences | 4 | $324 |
| E.r. Squibb & Sons, L.L.C. | 3 | $320 |
| Novartis | 20 | $298 |
| W. L. Gore & Associates, Inc. | 1 | $290 |
| Inspire Medical Systems, Inc. | 2 | $288 |
| Merck | 10 | $252 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $201 |
| Ancora Heart, Inc. | 3 | $186 |
| Irhythm Technologies, Inc. | 1 | $183 |
| Amgen | 16 | $159 |
| Briohealth Solutions, Inc. | 1 | $148 |
| Abiomed | 2 | $143 |
| Nuwellis, Inc. | 2 | $130 |
| Pfizer | 9 | $124 |
| KCI USA, Inc. | 1 | $99 |
| Cardiovascular Systems Inc. | 7 | $81 |
| Novo Nordisk | 3 | $59 |
| Johnson & Johnson | 4 | $48 |
| Picard Medical Inc. | 1 | $38 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$81,486
- CardioMEMS HF System$74,854
- Barostim Neo System$53,813
- VNS - Vitaria$29,100
- VNS Therapy$13,601
- MitraClip$9,775
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$7,293
- GENERAL - THERAPIES$4,288
- CARDIOMEMS$647
- HeartMate 3 Left Ventricular Dev$420
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$329
- Product in Development$290
- Reveal LINQ$249
- CAMZYOS$238
- ZIO XT Patch$183
- Inspire Upper Airway Stimulation System$157
- AccuCinch$149
- BRIOVAD$148
- MitraClip System$146
- Inspire$131
How this compares
$296,909 in reported general payments places this provider in the 95th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
See all advanced heart failure and transplant cardiology providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 365 | $426,921 |
| EntrestoSacubitril/Valsartan | 356 | $388,553 |
| EliquisApixaban | 217 | $193,661 |
| FarxigaDapagliflozin Propanediol | 78 | $67,272 |
| XareltoRivaroxaban | 62 | $50,308 |
| OzempicSemaglutide | 32 | $34,149 |
| Repatha SureclickEvolocumab | 22 | $23,888 |
| VerquvoVericiguat | 14 | $6,876 |
| Spironolactone | 448 | $3,464 |
| Torsemide | 167 | $3,290 |
| Metoprolol Succinate | 267 | $2,663 |
| Ranolazine ErRanolazine | 30 | $2,532 |
| Amiodarone Hcl | 59 | $2,363 |
| Eplerenone | 46 | $2,341 |
| Atorvastatin Calcium | 168 | $1,409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $65,124 | $426,921365 claims |
| NovartisEntresto | $298 | $388,553356 claims |
| PfizerEliquis | $124 | $193,661217 claims |
| AstraZenecaFarxiga | $1,931 | $67,27278 claims |
| Johnson & JohnsonXarelto | $48 | $50,30862 claims |
| Novo NordiskOzempic | $59 | $34,14932 claims |
| MerckVerquvo | $252 | $6,87614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
Other advanced heart failure and transplant cardiology in Cincinnati
- Ankit BhatiaCincinnati$141K
- Rachel GarciaCincinnati$104K
- Sateesh KesariCincinnati$101K
- Sitaramesh EmaniCincinnati$87K
- Gregory EgnaczykCincinnati$62K
- Santosh MenonCincinnati$30K
- Umama GorsiCincinnati$20K
- Stephanie DunlapCincinnati$9K
- Mahyar PourriahiCincinnati$8K
- Juliane ViereckeCincinnati$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.